Allurion Technologies performs reverse stock split to meet listing requirements
Allurion Technologies 執行反向股票分割以符合上市要求
更新於: 2026年6月18日 上午12:45
Allurion Technologies, a medical device company best known for its innovative, procedure-less swallowable gastric balloon for weight loss, has recently taken significant financial steps to remain listed on major stock exchanges.
Allurion Technologies(阿盧瑞科技)這家醫療設備公司，以其創新且無須手術的胃部減重氣球而聞名。
Like many small-cap companies facing price volatility, Allurion has used reverse stock splits to consolidate its shares and boost its market price.
該公司近期採取了重大的財務措施，以維持其在主要證券交易所的上市地位。
In January 2025, the company implemented a 1-for-25 reverse split to address concerns regarding the New York Stock Exchange's minimum bid price requirements.
與許多面臨股價波動的小型股公司一樣，Allurion 採用了股份合併（又稱反向拆股）來整併股票並提升市場價格。
This move was designed to help the company regain compliance with NYSE listing standards, effectively reducing its outstanding shares from 15 million to approximately 1 million.
隨後，由於市場壓力持續，Allurion 於 2026 年 6 月 18 日再次執行反向拆股，比率為 1 股換 15 股。
While these corporate actions are technical in nature—involving adjustments to equity awards and warrants—they highlight the operational challenges Allurion faces, including revenue contraction and the need to strengthen its overall capital market standing.
在轉換期間，股票在臨時代碼『ALURD』下交易，隨後恢復為『ALUR』。
